Changes after 12 weeks of etanercept therapy in the patient’s global assessment with regard to the technique of collection and consequently the Disease Activity Score in 108 patients with active rheumatoid arthritis.
| Outcome | Time | |||
|---|---|---|---|---|
| Baseline Visit* | Final Visit* | Change** (95% CI) | SRM (95% CI) | |
| PGA-HS | 5.9 ± 2.2 | 3.3 ± 2.5 | –2.51 (−2.98; −2.03) | 0.94 (0.69–1.26) |
| PGA-DA | 6.5 ± 1.9 | 3.3 ± 2.3 | –3.16 (−3.58; −2.74) | 1.36 (1.08–1.73) |
| PGA-RAID | 5.9 ± 1.7 | 3.0 ± 2.3 | –2.85 (−3.25; −2.45) | 1.37 (1.12–1.71) |
| DAS28-PGA-HS | 5.4 ± 0.8 | 3.4 ± 1.2 | –1.98 (−2.19; −1.77) | 1.84 (1.54–2.28) |
| DAS28-PGA-DA | 5.5 ± 0.8 | 3.4 ± 1.2 | –2.08 (−2.29; −1.87) | 1.94 (1.63–2.36) |
| DAS28-PGA-RAID | 5.4 ± 0.8 | 3.4 ± 1.2 | –2.04 (−2.25; −1.83) | 1.94 (1.63–2.37) |
↵* Mean ± SD.
↵** Adjusted mean change from baseline. PGA-HS: patient global assessment evaluated using a question related to health status; PGA-DA: PGA evaluated using a question related to rheumatoid arthritis disease activity; PGA-RAID: PGA evaluated using the RAID6. DAS28-PGA-HS: Disease Activity Score evaluated using the PGA-HS; DAS28-PGA-DA: DAS evaluated using the PGA-DA; DAS28-PGA-RAID: DAS evaluated using the PGA-RAID. SRM: standardized response mean (mean change/standard deviation of change).